|
p38 MAP Kinase Alpha Targeted Library |
 |
Ligand in p38 MAP Kinase Alpha active site. Docking example from p38 MAP Kinase Alpha Targeted Library.
The detection of H-bonds between ligand and key p38 MAP Kinase Alpha residue (Met109) was used for the library preparation.
|
It is now known that there are four members of the p38 MAP kinase family. They differ in their tissue distribution, regulation of kinase activation and subsequent phosphorylation of downstream substrates. They also differ in terms of their sensitivities toward the p38 MAP kinase inhibitors. The best-studied isoform is p38 alpha, whose activation has been observed in many hematopoietic and non-hematopoietic cell types upon treatment with appropriate stimuli.
The pyridinylimidazole compounds, exemplified by SB 203580, were originally prepared as inflammatory cytokine synthesis inhibitors that subsequently were found to be selective inhibitors of p38 MAP kinase. SB 203580 inhibits the catalytic activity of p38 MAP kinase by competitive binding in the ATP pocket. X-ray crystallographic studies of the target enzyme complexed with inhibitor reinforce the observations made from site-directed mutagenesis studies, thereby providing a molecular basis for understanding the kinase selectivity of these inhibitors.
The p38 MAP kinase inhibitors are efficacious in several disease models, including inflammation, arthritis and other joint diseases, septic shock, and myocardial injury. In all cases, p38 activation in key cell types correlated with disease initiation and progression. Treatment with p38 MAP kinase inhibitors attenuated both p38 activation and disease severity. Structurally diverse p38 MAP kinase inhibitors have been tested extensively in preclinical studies.
The targeted libraries, including docking scores and drug-like properties, are available on request.
Feel free to contact us!
Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL.
Inhibition of p38 MAP kinase as a therapeutic strategy.
Immunopharmacology. 2000 May;47(2-3):185-201. Review.
|
HOME
Overview
